Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration

Holekamp N.; Campochiaro P.; Chang Margaret A.; Miller Daniel; Pieramici D.; Adamis A.; Brittain C.; Evans Erica; Kaufman D.; Maass K.; Patel Shienal; Ranade S.; Singh Natasha; Barteselli Giulio; Regillo C.

doi:10.1016/j.ophtha.2021.09.016

← Today's brief

RCT

Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration

Holekamp N. et al. · Ophthalmology · Friday, January 1, 2021

Design Rctn 418Funding Not reported

Source

Holekamp N. et al.. Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. Friday, January 1, 2021.
doi:10.1016/j.ophtha.2021.09.016Read original ↗

Generated, then checked against the source · how this brief was built →

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.